Isaac Barchas

Director Isaac Barchas sells 100,000 shares (100.0K shares) for $2,412,521.54 via pre-arranged 10b5-1 plan

Isaac Barchas executed 2 separate sales totaling 100,000 shares for $2,412,521.54 on 2026-07-06 and 2026-07-07 at blended average price $24.13. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2026-03-31, meaning it was scheduled rather than discretionary. The sale reduced his holdings by 48.0%, from 208,504 shares to 108,504 shares post-transaction. At the same ticker IMNM, Barchas has prior sell history (2025-12-22) with modest 30-day returns (+14.5%, +11.3%) followed by negative 90-day returns (-7.9%, -10.4%), suggesting a pattern of near-term strength followed by longer-term underperformance after his sales. The company context shows material challenges: unprofitable with net income of $-53,839,000.00, full-year negative earnings, revenue of $0.00 in the latest quarter, and annual revenue decline of -23.2%.

Director Isaac Barchas sells 201,050 shares ($4.4M) at $21.12–$23.33 via pre-arranged 10b5-1 plan; retains 208,504 shares post-sale.

Director Isaac Barchas executed 3 separate sales totaling 201,050 shares for $4,393,024.30 on June 30 and July 2, 2026, reducing his stake from 409,554 shares to 208,504 shares (a -49.1% reduction in holdings). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-31, meaning the sales were scheduled in advance rather than discretionary. Immunome is unprofitable, with net income of -$53,839,000 over the most recent full fiscal year, annual revenue declined -23.2%, and the company reported $0.00 revenue in the latest quarter. The stock has appreciated +22.1% over the prior 30 days and currently trades at $23.61, though it remains -14.6% below its 52-week high of $27.65. Barchas's cross-ticker track record shows 2 prior open-market sales with an average 90-day return of -9.2%, while his 2 prior sales at IMNM (both on 2025-12-22) posted 90-day returns of -7.9% and -10.4%, suggesting his prior sales at this ticker have been followed by declines. The magnitude of the position reduction (49.1%) and the substantial dollar proceeds ($4.4M) warrant observation in the context of the company's fundamental challenges.

Director Barchas Isaac sold 383,200 shares (IMNM) for $8.3M via scheduled 10b5-1 plan on 2025-12-22

Barchas Isaac, a Director at Immunome Inc., executed 2 separate sales totaling 383,200 shares for $8,330,079.62 at a blended average price of $21.74 on 2025-12-22. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-05-23, meaning the timing and volume were scheduled in advance rather than discretionary. Post-transaction holdings stand at 2,031,181 shares, representing a 15.9% reduction from pre-transaction holdings of 2,414,381 shares. As a scheduled liquidation under a pre-existing plan, the sale reflects pre-planned capital management rather than an immediate response to current market conditions.